Rining Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rining Tang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Hong Zhi
Department of Cardiology, Zhongda Hospital of Southeast University, Nanjing, China
1 shared publication - Liqun Ren
Department of Geriatrics Medicine, Zhongda Hospital of Southeast University, Nanjing, China
1 shared publication - Naifeng Liu
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China; Affiliated Zhongda Hospital, Southeast University, Nanjing 210009, China
1 shared publication - Yanzhi Li
Department of Cardiology, Zhongda Hospital of Southeast University, Nanjing, China
1 shared publication - Ying-Juan Li
Department of Geriatrics, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, PR China
1 shared publication - Zulong Sheng
Department of Cardiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, China.
1 shared publication
Latest Publications
- Open Access
- 1 January 2011
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 10 (1) , 10
Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro
The peroxisome proliferator-activated receptor-γ (PPARγ) agonist rosiglitazone has been suggested to exert cardiovascular protection through the improvement of lipid metabolism, anti-inflammation, anti-proliferation etc. However, whether renin-angiotensin system (RAS) is involved in the vascular protective effects of PPARγ agonists is not fully understood. The present study aimed to investigate the effects of the renin-angiotensin system in vascular protection mediated by PPARγ agonists.
- 1 January 2011
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 10 (1) , 10
Open AccessVasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro
The peroxisome proliferator-activated receptor-γ (PPARγ) agonist rosiglitazone has been suggested to exert cardiovascular protection through the improvement of lipid metabolism, anti-inflammation, anti-proliferation etc. However, whether renin-angiotensin system (RAS) is involved in the vascular protective effects of PPARγ agonists is not fully understood. The present study aimed to investigate the effects of the renin-angiotensin system in vascular protection mediated by PPARγ agonists.